KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Finished Goods (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Finished Goods for 15 consecutive years, with $144.5 million as the latest value for Q4 2025.

  • Quarterly Finished Goods rose 1.06% to $144.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $144.5 million through Dec 2025, up 1.06% year-over-year, with the annual reading at $144.5 million for FY2025, 1.06% up from the prior year.
  • Finished Goods for Q4 2025 was $144.5 million at Halozyme Therapeutics, down from $161.6 million in the prior quarter.
  • The five-year high for Finished Goods was $164.9 million in Q2 2025, with the low at $25.8 million in Q4 2021.
  • Average Finished Goods over 5 years is $82.1 million, with a median of $61.1 million recorded in 2023.
  • Peak annual rise in Finished Goods hit 200.99% in 2021, while the deepest fall reached 16.39% in 2021.
  • Over 5 years, Finished Goods stood at $25.8 million in 2021, then skyrocketed by 78.28% to $46.0 million in 2022, then skyrocketed by 52.12% to $69.9 million in 2023, then skyrocketed by 104.41% to $142.9 million in 2024, then grew by 1.06% to $144.5 million in 2025.
  • According to Business Quant data, Finished Goods over the past three periods came in at $144.5 million, $161.6 million, and $164.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.